CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Meclizine Hydrochloride Tablets24-06-2020
24-06-2020
Cadila's renewed focus on India biz, Covid-19 opportunities lend confidence
Moving forward, Cadila's prospects in the domestic market remain firm led by its strong product range and renewed business strategy23-06-2020
CADILA HEALTHCARE LTD. - 532321 - Participation In Investor Conference
Participation in Investor Conference23-06-2020
CADILA HEALTHCARE LTD. - 532321 - Participation In Investor Conference
Participation in Investor Conference23-06-2020
Cadila-CSIR's sepsis drug shows promise in fight against Covid-19
The public-private partnership trial-generated data will be soon presented before the country's drug regulator to see if it can get emergency-use authorisation.22-06-2020
Slowing growth momentum may weigh on Cadila Healthcare stock
The US market did not quite seem to benefit from the pre-covid-19 stocking, with revenues falling about 2% year-on-year. Domestic revenues were flat in Q422-06-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication with regard to audited financial results for the quarter / year ended on March 31, 2020.21-06-2020
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance19-06-2020